Related Experiment Video
Updated: May 1, 2026

Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
Published on: August 19, 2020
A positive feedback loop involving Erk5 and Akt turns on mesangial cell proliferation in response to PDGF
Amit Bera1, Falguni Das1, Nandini Ghosh-Choudhury2
1Department of Medicine, University of Texas Health Science Center, San Antonio, Texas; and.
Abstract:
Platelet-derived growth factor BB and its receptor (PDGFRβ) play a pivotal role in the development of renal glomerular mesangial cells. Their roles in increased mesangial cell proliferation during mesangioproliferative glomerulonephritis have long been noted, but the operating logic of signaling mechanisms regulating these changes remains poorly understood. We examined the role of a recently identified MAPK, Erk5, in this process. PDGF increased the activating phosphorylation of Erk5 and tyrosine phosphorylation of proteins in a time-dependent manner. A pharmacologic inhibitor of Erk5, XMD8-92, abrogated PDGF-induced DNA synthesis and mesangial cell proliferation. Similarly, expression of dominant negative Erk5 or siRNAs against Erk5 blocked PDGF-stimulated DNA synthesis and proliferation. Inhibition of Erk5 attenuated expression of cyclin D1 mRNA and protein, resulting in suppression of CDK4-mediated phosphorylation of the tumor suppressor protein pRb. Expression of cyclin D1 or CDK4 prevented the dominant negative Erk5- or siErk5-mediated inhibition of DNA synthesis and mesangial cell proliferation induced by PDGF. We have previously shown that phosphatidylinositol 3-kinase (PI3-kinase) contributes to PDGF-induced proliferation of mesangial cells. Inhibition of PI3-kinase blocked PDGF-induced phosphorylation of Erk5. Since PI3-kinase acts through Akt, we determined the role of Erk5 on Akt phosphorylation. XMD8-92, dominant negative Erk5, and siErk5 inhibited phosphorylation of Akt by PDGF. Interestingly, we found inhibition of PDGF-induced Erk5 phosphorylation by a pharmacological inhibitor of Akt kinase and kinase dead Akt in mesangial cells. Thus our data unfold the presence of a positive feedback microcircuit between Erk5 and Akt downstream of PI3-kinase nodal point for PDGF-induced mesangial cell proliferation.
Insights
Platelet-derived growth factor BB (PDGF) signaling in kidney cells involves a feedback loop between Erk5 and Akt, crucial for mesangial cell proliferation in glomerulonephritis.
Area of Science:
- Nephrology
- Cell Signaling
- Molecular Biology
Background:
- Platelet-derived growth factor BB (PDGF) and its receptor (PDGFRβ) are key in renal glomerular mesangial cell development.
- Increased mesangial cell proliferation in mesangioproliferative glomerulonephritis is linked to PDGF, but underlying signaling is unclear.
Purpose of the Study:
- To investigate the role of the mitogen-activated protein kinase (MAPK) Erk5 in PDGF-induced mesangial cell proliferation.
- To elucidate the signaling mechanisms connecting Erk5, Akt, and phosphatidylinositol 3-kinase (PI3-kinase) in this process.
Main Methods:
- Utilized PDGF stimulation in mesangial cells.
- Employed Erk5 inhibitor (XMD8-92), dominant-negative Erk5, and Erk5 siRNAs.
- Assessed DNA synthesis, cell proliferation, and protein/mRNA expression (cyclin D1, CDK4, pRb, Akt phosphorylation).
Main Results:
- PDGF increased Erk5 phosphorylation; Erk5 inhibition blocked PDGF-induced proliferation.
- Erk5 inhibition reduced cyclin D1 and CDK4, inhibiting pRb phosphorylation.
- A positive feedback loop between Erk5 and Akt, downstream of PI3-kinase, was identified, regulating PDGF-induced proliferation.
Conclusions:
- Erk5 is essential for PDGF-induced mesangial cell proliferation.
- A PI3-kinase-dependent positive feedback microcircuit between Erk5 and Akt regulates PDGF signaling in mesangial cells.
More Related Videos
Related Concept Videos
MAPK Signaling Cascades
Amplifying Signals via Enzymatic Cascade
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
TGF - β Signaling Pathway
cAMP-dependent Protein Kinase Pathways

